Acorda Presenting New Tozadenant Data at 2017 MDS Congress

ARDSLEY, N.Y.–(BUSINESS WIRE)– Acorda Therapeutics, Inc. (Nasdaq: ACOR)
is presenting new data from clinical and preclinical studies of
tozadenant at the 2017 International Congress of Parkinson’s Disease and
Movement Disorders (MDS), being held in Vancouver, British Columbia from
June 4-8, 2017. Acorda is developing tozadenant as a daily maintenance
therapy to reduce OFF time for people with Parkinson’s taking an oral
carbidopa / levodopa regimen. OFF refers to the re-emergence of
Parkinson’s symptoms.

“OFF is cited by people with Parkinson’s as one of the most challenging
aspects of their disease to manage,” said Burkhard Blank, M.D., Acorda’s
Chief Medical Officer. “Tozadenant represents a potential first-in-class
treatment for Parkinson’s in the U.S. that is being studied to reduce
overall daily OFF time.”

Tozadenant data being presented at the MDS congress include:

• Associating patient impression of improvement with efficacy endpoints
  in Parkinson’s disease: A post-hoc analysis of a tozadenant study
  (abstract #1433)
• Tozadenant phase 3 study (TOZ-PD) in Parkinson’s disease patients with
  motor fluctuations: baseline characteristics (abstract #1432)
• Efficacy of tozadenant in animal models of non-motor symptoms of
  Parkinson’s disease (abstract #120)

Acorda expects results from an ongoing tozadenant Phase 3 clinical trial
in Q1 2018. In addition, the Company initiated an open-label, long-term
safety study in the second quarter of 2017.

About Parkinson’s Disease and OFF

Approximately one million people in the U.S. and 1.2 million Europeans
are diagnosed with Parkinson’s disease (PD); OFF periods are experienced
by approximately 350,000 in the U.S. and 420,000 in Europe.

Parkinson’s is a progressive neurodegenerative disorder resulting from
the gradual loss of certain neurons responsible for producing dopamine.
It causes a range of symptoms including impaired movement, muscle
stiffness and tremors. As PD progresses, people with Parkinson’s
experience OFF periods, which are characterized by the re-emergence of
PD symptoms. This re-emergence can occur even when an individual’s
treatment regimen has been optimized.

OFF periods can be very disruptive to the lives of people with
Parkinson’s, their families and caregivers. OFF periods can increase in
frequency and severity during the course of the disease.

About Acorda Therapeutics

Founded in 1995, Acorda Therapeutics is a biopharmaceutical company
focused on developing therapies that restore function and improve the
lives of people with neurological disorders. Acorda has a pipeline of
novel neurological therapies addressing a range of disorders, including
Parkinson’s disease and multiple sclerosis. Acorda markets
three FDA-approved therapies, including AMPYRA^®
(dalfampridine) Extended Release Tablets, 10 mg. For more information,
please visit the Company’s website at: www.acorda.com.

Forward-Looking Statement

This press release includes forward-looking statements. All statements,
other than statements of historical facts, regarding management’s
expectations, beliefs, goals, plans or prospects should be considered
forward-looking. These statements are subject to risks and uncertainties
that could cause actual results to differ materially, including: the
ability to realize the benefits anticipated from the Biotie and Civitas
transactions, among other reasons because acquired development programs
are generally subject to all the risks inherent in the drug development
process and our knowledge of the risks specifically relevant to acquired
programs generally improves over time; the ability to successfully
integrate Biotie’s operations and Civitas’ operations, respectively,
into our operations; we may need to raise additional funds to finance
our expanded operations and may not be able to do so on acceptable
terms; our ability to successfully market and sell Ampyra
(dalfampridine) Extended Release Tablets, 10 mg in the U.S., which will
likely be materially adversely affected by the recently announced court
decision in our litigation against filers of Abbreviated New Drug
Applications (each, an “ANDA”) to market generic versions of Ampyra in
the U.S.; third party payers (including governmental agencies) may not
reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization
requirements that limit or block prescriptions; the risk of unfavorable
results from future studies of Ampyra or from our other research and
development programs, including INBRIJA (CVT-301, levodopa inhalation
powder), or any other acquired or in-licensed programs; we may not be
able to complete development of, obtain regulatory approval for, or
successfully market INBRIJA, any other products under development, or
the products that we acquired with the Biotie transaction; the
occurrence of adverse safety events with our products; delays in
obtaining or failure to obtain and maintain regulatory approval of or to
successfully market Fampyra outside of the U.S. and our dependence on
our collaborator Biogen in connection therewith; competition; failure to
protect our intellectual property, to defend against the intellectual
property claims of others or to obtain third party intellectual property
licenses needed for the commercialization of our products; and failure
to comply with regulatory requirements could result in adverse action by
regulatory agencies.

These and other risks are described in greater detail in our filings
with the Securities and Exchange Commission. We may not actually achieve
the goals or plans described in our forward-looking statements, and
investors should not place undue reliance on these statements.
Forward-looking statements made in this press release are made only as
of the date hereof, and we disclaim any intent or obligation to update
any forward-looking statements as a result of developments occurring
after the date of this press release.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170606005215/en/